ProVise Management Group LLC trimmed its stake in Novartis AG (NYSE:NVS – Free Report) by 3.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 129,971 shares of the company’s stock after selling 4,129 shares during the period. Novartis comprises about 1.3% of ProVise Management Group LLC’s investment portfolio, making the stock its 24th largest position. ProVise Management Group LLC’s holdings in Novartis were worth $18,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently bought and sold shares of the stock. Highland Investment Advisors LLC acquired a new stake in shares of Novartis in the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. increased its position in shares of Novartis by 552.0% during the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock worth $26,000 after purchasing an additional 138 shares in the last quarter. Atlatl Advisers LLC acquired a new stake in shares of Novartis during the 2nd quarter worth about $26,000. Silicon Valley Capital Partners increased its position in shares of Novartis by 519.4% during the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock worth $30,000 after purchasing an additional 161 shares in the last quarter. Finally, Curry Webb Wealth Management LLC bought a new position in Novartis during the 3rd quarter valued at about $28,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
NVS has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of Novartis from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis in a research note on Sunday, August 9th. Sanford C. Bernstein reaffirmed a “neutral” rating on shares of Novartis in a report on Wednesday, July 22nd. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Novartis in a research report on Wednesday, October 28th. Finally, Citigroup restated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Six investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $152.25.
Check Out Our Latest Stock Analysis on Novartis
Novartis Price Performance
Novartis stock opened at $160.59 on Monday. The business’s 50-day simple moving average is $149.13 and its 200 day simple moving average is $152.60. The stock has a market cap of $306.42 billion, a price-to-earnings ratio of 30.65, a P/E/G ratio of 2.94 and a beta of 0.40. Novartis AG has a 12-month low of $123.24 and a 12-month high of $170.46. The company has a quick ratio of 0.70, a current ratio of 0.88 and a debt-to-equity ratio of 0.98.
Novartis (NYSE:NVS – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.25 by $0.21. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.53 billion. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The company’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the company earned $2.25 earnings per share. As a group, research analysts anticipate that Novartis AG will post 9.10 earnings per share for the current year.
About Novartis
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Featured Stories
- Five stocks we like better than Novartis
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
